Comment on “A phase IB/IIA study of ex vivo expanded allogeneic bone-marrow-derived mesenchymal stem cells for the treatment of rectovaginal fistulizing Crohn disease.”

We read with great interest the study by Lightner et  al,1 who aimed to determine the safety and efficacy of mesenchymal stem cells (MSCs) for refractory rectovaginal fistulizing Crohn disease (CD). They found that bone-marrow-derived MSCs offer a safe alternative treatment approach for rectovaginal fistulas in the setting of CD. Complete healing was achieved in half of the patients. We appreciate the authors’ hard work. However, we have a few comments on the article. Meanwhile, we recommend additional propensity score matching to balance the baseline information.
Source: Surgery - Category: Surgery Authors: Source Type: research